Table 2. Simultaneous treatment with... | American Society of Hematology

Table 2.

Simultaneous treatment with CEP-701 and chemotherapy

	Cytarabine					Daunorubicin					Etoposide
	IC_50, nM	CI, 10 nM	CI, 20 nM	IC_50, nM	CI, 10 nM	CI, 20 nM	IC_50, nM	CI, 10 nM	CI, 20 nM	IC_50, nM	CI, 10 nM	CI, 20 nM
MV4-11	7338	0.593	0.672	48	0.768	0.557	169	0.362	0.414	9	0.596	0.581
BaF3/ITD	6289	0.783	0.856	40	0.164	0.069	182	0.182	0.135	5	0.327	0.400
AML/ITD	3152	0.465	0.629	33	0.497	0.393	1514	0.761	0.765	14	0.508	0.590
HL60	734	0.980	1.046	56	0.895	0.754	1055	1.047	1.112	54	0.885	1.105

	Cytarabine					Daunorubicin					Etoposide
	IC_50, nM	CI, 10 nM	CI, 20 nM	IC_50, nM	CI, 10 nM	CI, 20 nM	IC_50, nM	CI, 10 nM	CI, 20 nM	IC_50, nM	CI, 10 nM	CI, 20 nM
MV4-11	7338	0.593	0.672	48	0.768	0.557	169	0.362	0.414	9	0.596	0.581
BaF3/ITD	6289	0.783	0.856	40	0.164	0.069	182	0.182	0.135	5	0.327	0.400
AML/ITD	3152	0.465	0.629	33	0.497	0.393	1514	0.761	0.765	14	0.508	0.590
HL60	734	0.980	1.046	56	0.895	0.754	1055	1.047	1.112	54	0.885	1.105

IC₅₀ and CI values for the combination of 10 or 20 nM CEP-701 and chemotherapeutic agents at doses corresponding to the approximate IC₅₀. In this simultaneous treatment scenario, triplicate samples of cells were simultaneously exposed to CEP-701 and the chemotherapeutic agent for 48 hours, and then MTT assays were performed. Each CI value was obtained by conducting dose-response experiments for CEP-701 and the indicated chemotherapy individually and in combination over a range of doses for both drugs. The values shown are representative of 3 different experiments.

View Large

This Feature Is Available To Subscribers Only